Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
Primary endpoints: The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR \<60 ml/min/1.73 m2 (CFR categories C3a-C5). Secondary endpoints: The following secondary endpoints will be evaluated in all patients with AH and markers of CKD included in the study (Full Analysis Sampling - FAS) (Secondary Aim 1) and in the subgroup of patients with a diagnosis of CKD confirmed during the study (Modified Full Analysis Sampling - mFAS), i.e., at Visit 1 or Visit 2 (Secondary Aim 2):
Study Type
OBSERVATIONAL
Enrollment
1,283
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR \<60 ml/min/1.73 m2 (CFR categories C3a-C5).
Time frame: 16 months
1. Frequency of microalbuminuria, proteinuria, reduced glomerular filtration rate (GFR <60 ml/min/1.73 m²) and other markers of kidney damage in patients with arterial hypertension.
1\. Frequency of microalbuminuria, proteinuria, reduced glomerular filtration rate (GFR \<60 ml/min/1.73 m²) and other markers of kidney damage in patients with arterial hypertension.
Time frame: 16 months
2. Proportion of patients with various risk factors (age, gender, BMI, bad habits, blood pressure, cardiovascular risks) for the development and progression of CKD in patients with arterial hypertension.
2\. Proportion of patients with various risk factors (age, gender, BMI, bad habits, blood pressure, cardiovascular risks) for the development and progression of CKD in patients with arterial hypertension.
Time frame: 16 months
3.Proportion of patients with various clinical characteristics, such as: • Average and median duration of AH years • Patients with different stages of AH and categories of cardiovascular risk.• Patients with uncontrolled and resistant hypertension.
3\. Proportion of patients with various clinical characteristics, such as: * Average and median duration of hypertension, years (from the diagnosis date to Visit 1); * Patients with different stages of hypertension (I, II, III) and categories of cardiovascular risk (low, moderate, high, very high). * Patients with uncontrolled and resistant hypertension.
Time frame: 16 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ordabasy Central District Hospital
Temirlanovka, Turkistan Oblast, Kazakhstan
City Polyclinic No. 4
Aktobe, Kazakhstan
City Cardiology Center
Almaty, Kazakhstan
Interna Clinic, Scientific Centre for Internal Medicine LLP
Almaty, Kazakhstan
JSC Research Institute of Cardiology and Internal Diseases
Almaty, Kazakhstan
LLP Almaty Sema Hospital
Almaty, Kazakhstan
Municipal state enterprise with the right of economic management City polyclinic No. 5
Almaty, Kazakhstan
National Hospital of Medical Center of the Presidents Affairs Administration of the Republic of Kazakhstan
Almaty, Kazakhstan
AIS Clinic
Astana, Kazakhstan
City Polyclinic No. 2
Astana, Kazakhstan
...and 18 more locations
4. The proportion of patients taking the following groups of drugs for the treatment of AH before inclusion in the study and during participation in the study: • ACE • Alfa or Beta-blockers; • ARBs •CCB • Diuretics • ARNI• Centrally acting drugs; • MRA.
4\. The proportion of patients taking the following groups of drugs for the treatment of hypertension before inclusion in the study and during participation in the study: * ACE (angiotensin-converting enzyme) inhibitors; * Beta-blockers; * ARBs (angiotensin receptor blockers); * Calcium channel blockers (CCB); * Diuretics (thiazide, thiazide-like, loop); * Angiotensin receptor-neprilysin inhibitor (ARNI); * Alpha-blockers; * Centrally acting drugs; * Mineralocorticoid receptor antagonists (MRA).
Time frame: 16 months
5. Proportion of patients with: • concomitant CVD and complications of AF/AFL, ventricular arrhythmias; CHD; MI; cerebrovascular diseases; stroke, TIA; • other concomitant diseases (in general and for each disease).
5\. Proportion of patients with: * concomitant cardiovascular diseases (CVD) and complications of hypertension (atrial fibrillation/atrial flutter (AF/AFL), ventricular arrhythmias; coronary heart disease (CHD); myocardial infarction (MI); cerebrovascular diseases; stroke, transient ischemic attack (TIA); * other concomitant diseases (in general and for each disease).
Time frame: 16 months